The Heads of Medicines Agencies (HMA), which is part of the European medicines regulatory network, is increasingly harmonising the way National Competent Authorities (NCAs) do their work.

As part of this process it has published this guidance with a view to forming a unified approach to the management of conflicts of interests across member states.

The guidelines are intended to assist the NCAs, which together form the HMA, to effectively manage declarations of interest so that they can ensure the highest possible common standards of impartiality and independence.

Latest version of the HMA Guide to Managing Declarations of Interest is avalable at the following LINK (under Key documents).

Transparency guideline

Press Release | pdf
EMA / HMA Guidance on the identification of commercially confidential information and personal data | pdf
EMA / HMA: Principles to be applied to the guidance document, adopted in March 2012 | pdf
Summary of the comments received to the above document, published in July 2012 | pdf